Background—Randomized controlled trials have reported favorable 1-year outcomes with
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …

Purpose: To evaluate the efficacy of intravascular stents used to treat long-segment
stenoses and occlusions of the superficial femoral artery (SFA) after suboptimal angioplasty …

Purpose: To determine and compare the rates of in-stent restenosis, late clinical
deterioration, and stent fractures in nitinol stents versus Wallstents implanted for suboptimal …

Objectives The purpose of this study was to assess the safety and performance of Stellarex
Drug‐coated balloon (DCB). Background DCB coatings differ in excipients, paclitaxel dose …

Objectives To assess the longer‐term safety and efficacy of the IN. PACT Admiral (MDT‐
2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic …

Purpose: To assess the safety and effectiveness of the MDT-2113 (IN. PACT Admiral) drug-
coated balloon (DCB) for the treatment of de novo and native artery restenotic lesions in the …

Abstract Objectives: The Global SFA Registry sought to assess safety, clinical benefit, and
outcomes of the Lutonix 035 drug-coated balloon (DCB) in a heterogeneous, real-world …

Objectives: This study sought to evaluate the outcomes of drug-eluting stent treatment for
femoropopliteal in-stent restenosis (ISR). Background: ISR after femoropopliteal …

Background Long-term data on drug-coated balloon (DCB) outcomes in complex
femoropopliteal atherosclerotic lesions are limited. Objectives The authors sought to report 5 …

Background: Drug-eluting technologies improve 12-month angiographic results of
femoropopliteal (FP) interventions, but few data on the comparison between drug-coated …